Clinical Trial Update: Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A [Phase 1]

View source ↗

Summary

This Phase 1 trial assessed the pharmacokinetics of standard half-life FVIII, extended half-life FVIII, and efanesoctocog alfa (BIVV001) in individuals with sev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Extended Half-Life Factor VIII (Factor VIII)
• Standard Half-Life Factor VIII (Factor VIII)
• efanesoctocog alfa (BIVV001) (efanesoctocog alfa)

Snippet

Sponsor: Sanofi | Conditions: Hemophilia A | Phase 1 | Status: COMPLETED